40

Listed companies

22

Private companies

80

Insiders

Relation chart of related listed companies: Moderna, Inc.

Active Relations

Past Relations

Related listed companies: Moderna, Inc.

Active Relations

Past Relations

Relationship chart for related private companies: Moderna, Inc.

Active Relations

Past Relations

Related private companies: Moderna, Inc.

TARIS BioMedical LLC

Pharmaceuticals: Major

YourBio Health, Inc.

Medical Specialties

Harvard University

Other Consumer Services

Massachusetts Institute of Technology

Finance/Rental/Leasing

American Bar Association

Miscellaneous Commercial Services

QIAGEN GmbH

Miscellaneous Commercial Services

American Academy of Arts & Sciences

Miscellaneous Commercial Services

National Academy of Medicine (United States)

Miscellaneous Commercial Services

Longwood Fund Management LLC

Investment Managers

Qiagen SRL

Medical Specialties

David H. Koch Institute for Integrative Cancer Research

Miscellaneous Commercial Services

Indigo Ag, Inc.

Biotechnology

Ring Therapeutics, Inc.

Pharmaceuticals: Major

Repertoire Immune Medicines, Inc.

Pharmaceuticals: Major

Tessera Therapeutics, Inc.

Biotechnology

Inzen Therapeutics, Inc.

Biotechnology

Generate Biomedicines, Inc.

Biotechnology

Vesalius Therapeutics

Biotechnology

Sail Biomedicines

Pharmaceuticals: Major

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Biotechnology23
Pharmaceuticals: Major14
Medical Specialties6
Miscellaneous Commercial Services5
Investment Managers3
Packaged Software3
Finance/Rental/Leasing1
Other Consumer Services1
Pharmaceuticals: Other1
Internet Software/Services1

Countries of related companies

United States50
Switzerland4
United Kingdom2
Italy1
Germany1
Ireland1
Canada1
Netherlands1
Israel1
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW